v3.26.1
OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS
3 Months Ended
Mar. 31, 2026
Payables and Accruals [Abstract]  
OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS
Accrued liabilities consisted of the following as of March 31, 2026 and December 31, 2025:
(In thousands)MARCH 31,
2026
DECEMBER 31,
2025
Contract research organization and clinical trial costs$4,696 $3,677 
Manufacturing activities16,107 38,657 
Professional, legal and accounting fees2,632 881 
Interest payable— 3,110 
Accrued revenue adjustments5,562 3,486 
Other 1,968 1,529 
$30,965 $51,340 
Accrued compensation and benefits consisted of the following as of March 31, 2026 and December 31, 2025:
(In thousands)MARCH 31,
2026
DECEMBER 31,
2025
Accrued bonuses$3,530 $10,335 
Accrued vacation2,405 2,581 
Accrued restructuring charges3,106 17,032 
Accrued other447 549 
$9,488 $30,497